logo Click here for the Institute for Clinical and Translational Science Home Page Click here for the UC Irvine Home Page
Dan Mercola, MD, PhD
Professor, Pathology and Laboratory Medicine, UC Irvine Director, Translational Cancer Biology, UC Irvine
Current PI funding: NIH (U01-CA114810), Predictive signatures of prostate cancer (2005-2010) DOD (BC050883), Sensitization of breast cancer to herceptin (2006-2009) Susan G. Komen Foundation (BCTR65506), Chemotherapy resistance by breast cancer (2006-2009) Mary Kay Ash Foundation (082-07), Diagnostic test for breast cancer (2007-2009)
Mentoring: Dr. Mercola has an outstanding pedigree and mentoring record. Trained by Nobel Laureate Dr. Dorothy Hodgkin at the University of Oxford, Dr. Mercola has mentored 52 trainees (plus 5 another currently), many of whom have progressed to prominent leadership positions, such as Dr. Philip Carpenter, Professor and Director of Anatomical Pathology at UC Irvine; Dr. Olga Potapova, CEO of Curline Inc. in San Francisco; and Dr. Guiseppe Ragone, Professor and Chair of Experimental Pathology at the University of Rome, Italy.
Research: Dr. Mercola is an experienced and innovative translational scientist. In addition to directing Translational Cancer Biology at UC Irvine since 2005, he is PI of the UC Irvine Strategic Partners for the Evaluation of Signatures of Cancer (SPECS) consortium, which liaises with seven external institutes for the development of prognostic biomarkers using genomic methods. Results of these studies have been used for patent filing by UC Irvine and have been exclusively licensed to Proveri Inc., a company cofounded by Dr. Mercola to develop the translation of SPECS IP. Dr. Mercola was also a co-developer of chromatin immunoprecipitation for the analysis of cancer cells. He was selected as “San Diego Padres Medical All-Star” for 2004.